Lukas Flatz et al. have exploited the characteristics of the lymphocytic choriomeningitis virus (LCMV) to create a vaccine vector platform that elicits potent CD8+ T cell immunity. Using a recombinant, replication-defective LCMV, they show that these modified viral vectors target dendritic cells in vivo and trigger cytotoxic T lymphocyte responses that compare favorably with existing vectors. Other benefits include low global seroprevalence to LCMV and minimal interference of preexisting antibodies with vaccine efficacy.
- Lukas Flatz
- Ahmed N Hegazy
- Daniel D Pinschewer
